argenx SE reported $2.6B in Cash and Equivalent for its fiscal quarter ending in September of 2026.





Cash And Equivalent Change Date
AstraZeneca USD 4.89B 2.67B Jun/2026
Genmab DKK 1.5B 18M Jun/2026
GlaxoSmithKline GBP 3.1B 337M Jun/2026
GRIFOLS EUR 486M 27M Sep/2026
Hikma Pharmaceutical USD 217M 19M Dec/2025
Lakefront Biotherapeutics EUR 94.66M 41.3M Sep/2026
Qiagen NV USD 768.5M 122.21M Jun/2026
UCB EUR 1.57B 1.14B Dec/2024